Access plan provides scientists performing high content screening with a more flexible and economical way to purchase and utilise applications
Cellomics has announced its CellSelect BioApplication access plan.
For scientists performing high content screening (HCS) "the CellSelect access plan provides customers with a more flexible and economical way to purchase and utilise our 17 powerful BioApplications" according to Sarah Burroughs Tencza, product manager at Cellomics.
"Cellomics has the largest portfolio of BioApplications available, and the CellSelect access plan will increase the productivity of our HCS customers so that HCS assays can be used in a broader range of drug discovery and therapeutic programs".
CellSelect BioApplication packages enable scientists to purchase more image analysis algorithms for their ArrayScan HCS readers and vHCS Discovery Toolbox, enhancing the flexibility of the system.
The four different access plan levels, bronze, silver, gold, and platinum, provide progressive discounts on BioApplications as well as other benefits and services including new BioApplications, training, reagents, and enhanced customer support.
CellSelect will further expand the role of HCS in drug discovery," said Tencza.
By utilising this large portfolio of easy-to-use, and in some cases patented, algorithms, drug discovery companies can extend the benefits of HCS into all of their therapeutic areas for target identification and lead optimisation, through the process to toxicology testing. "Our customers can now realise the full potential of HCS through our many BioApplications and easily see the value in accessing our portfolio of current and future releases."
